Jacobio’s ladder

How Chinese R&D incubator Jacobio plans to deploy its $55M series C

Beijing Jacobio Pharmaceutical Co. Ltd. plans to use its $55 million series C round to fuel its creation of spinouts housing internally developed assets.

Existing investor Qiming Venture Partners led the tranched round, which closed on Aug. 30 with participation

Read the full 392 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE